Elite Pharmaceuticals, Inc. engages in the development and manufacture of pharmacological abuse-deterrent opioid products. It operates through the Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA) segments. The ANDA segment includes generic pharmaceuticals. The NDA segment comprises the branded pharmaceuticals. The company was founded on October 1, 1997 and is headquartered in Northvale, NJ.